Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Alimentary Pharmacology & Therapeutics
|
October 15, 2013
A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis
N A Kennedy, E Rhatigan, I D R Arnott, et al.
Clinical and Experimental Immunology
|
March 11, 2004
Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations
L J Walker, M C Aldhous, H E Drummond, et al.
Inflammatory Bowel Diseases
|
July 21, 2009
Lack of association between cervical dysplasia and IBD: a large case-control study
C W Lees, J Critchley, N Chee, et al.
Genes and Immunity
|
June 20, 2008
Detailed assessment of NOD2/CARD15 exonic variation in inflammatory bowel disease in Scotland: implications for disease pathogenesis
R K Russell, H E Drummond, D C Wilson, et al.
Alimentary Pharmacology & Therapeutics
|
July 20, 2007
A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis
C W Lees, D Heys, G T Ho, et al.
Genes and Immunity
|
June 11, 2004
NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe?
I D R Arnott, E R Nimmo, H E Drummond, et al.
Inflammatory Bowel Diseases
|
November 20, 2009
Magnetic resonance follow-through imaging for evaluation of disease activity in ileal Crohn's disease: an observational, retrospective cohort study
C A Parisinos, V E D McIntyre, T Heron, et al.
Journal of Pediatric Gastroenterology and Nutrition
|
January 31, 2009
Anti-Saccharomyces cerevisiae antibodies status is associated with oral involvement and disease severity in Crohn disease
R K Russell, B Ip, M C Aldhous, et al.
Alimentary Pharmacology & Therapeutics
|
January 10, 2009
The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up
C W Lees, A I Ali, A I Thompson, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Alimentary Pharmacology & Therapeutics
|
October 15, 2013
A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis
N A Kennedy, E Rhatigan, I D R Arnott, et al.
Clinical and Experimental Immunology
|
March 11, 2004
Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations
L J Walker, M C Aldhous, H E Drummond, et al.
Inflammatory Bowel Diseases
|
July 21, 2009
Lack of association between cervical dysplasia and IBD: a large case-control study
C W Lees, J Critchley, N Chee, et al.
Genes and Immunity
|
June 20, 2008
Detailed assessment of NOD2/CARD15 exonic variation in inflammatory bowel disease in Scotland: implications for disease pathogenesis
R K Russell, H E Drummond, D C Wilson, et al.
Alimentary Pharmacology & Therapeutics
|
July 20, 2007
A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis
C W Lees, D Heys, G T Ho, et al.
Genes and Immunity
|
June 11, 2004
NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe?
I D R Arnott, E R Nimmo, H E Drummond, et al.
Inflammatory Bowel Diseases
|
November 20, 2009
Magnetic resonance follow-through imaging for evaluation of disease activity in ileal Crohn's disease: an observational, retrospective cohort study
C A Parisinos, V E D McIntyre, T Heron, et al.
Journal of Pediatric Gastroenterology and Nutrition
|
January 31, 2009
Anti-Saccharomyces cerevisiae antibodies status is associated with oral involvement and disease severity in Crohn disease
R K Russell, B Ip, M C Aldhous, et al.
Alimentary Pharmacology & Therapeutics
|
January 10, 2009
The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up
C W Lees, A I Ali, A I Thompson, et al.
Page
of 2